5-HT2b antagonists (Evotec/Boehringer Ingelheim)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Name5-HT2b antagonists (Evotec/Boehringer Ingelheim)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2b (5-HT2b) receptor antagonists
TargetsSerotonin 2b (5-HT2b) receptor
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEvotec SE
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim International GmbhEvotec SE
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A